Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 4—April 2022

Rigidoporus corticola Colonization and Invasive Fungal Disease in Immunocompromised Patients, United States

Alvaro C. LagaComments to Author , Jessica W. Crothers, Connie F. Cañete-Gibas, Nathan P. Wiederhold, and Isaac H. Solomon
Author affiliations: Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA (A.C. Laga, I.H. Solomon); University of Vermont Medical Center, Burlington, Vermont, USA (J.W. Crothers); University of Texas Health San Antonio, San Antonio, Texas, USA (C.F. Cañete-Gibas, N.P. Wiederhold)

Main Article


Clinical, microbiologic, and histopathologic features of Rigidoporus corticola infection in 2 immunocompromised patients, United States*

Characteristics Patient 1 Patient 2
Age, y/sex 43/M 63/M
Underlying conditions Acute myeloid leukemia, chronic granulomatous disease, hematopoietic stem cell transplant Recurrent lung cancer, chemotherapy
Clinical manifestations Hemifacial pain; sinusitis Right lung nodule
Identification method Broad-range fungal PCR, then sequencing from tissue culture for internal transcribed spacer and D1/D2 subregions (98.5%–100% identity) Broad-range fungal PCR assay, then sequencing from formalin-fixed, paraffin-embedded tissue
Susceptibility testing Posaconazole (MIC 8 µg/mL), voriconazole (MIC 0.5 µg/mL), isavuconazole (MIC 1.0 µg/mL) Not done
Pathologic diagnosis Invasive fungal sinusitis Fungus ball
Specimen type Sinus debridement tissue Lung wedge resection
Histologic pattern Hyphae invading vessels and bone Hyphae in sclerotic cavity; no invasion
Branching degree Predominantly 90° Predominantly 90°
Clamp connections Y N
Vascular invasion Y N
Treatment Surgical debridement, amphotericin B, voriconazole, isavuconazole, olorofim Surgical debridement
Response No disease on endoscopy at 6 mo; new pulmonary nodule at 9 mo No disease after resection
Outcome Death from invasive fungal disease aftet 10 mo Death from recurrent lung cancer after 11 mo

Main Article

Page created: February 24, 2022
Page updated: March 19, 2022
Page reviewed: March 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.